.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,212,200

« Back to Dashboard

Claims for Patent: 5,212,200

Title: Ocular hypotensive agents
Abstract:The present invention relates to ocular hypotensive agents which contains 13,14-dihydro-15-keto-prostagrandins, which shows no transient ocular hypertensive response that PGs usually show.
Inventor(s): Ueno; Ryuzo (Nishinomiya, JP), Ueno; Ryuiji (Nishinomiya, JP)
Assignee: R-Tech Ueno, Ltd. (Osaka, JP)
Application Number:07/760,280
Patent Claims: 1. A topical ocular composition comprising an amount effective as an ocular hypotensive agent of a 13,14-dihydro-15-keto-prostaglandin represented by the following formula (I): ##STR16## wherein A is ##STR17## wherein R is hydroxy, hydroxy C.sub.1-3 alkyl or C.sub.1-2 alkyl; Y is a saturated or unsaturated C.sub.2-6 hydrocarbon chain which is unsubstituted or substituted by oxo, halogen, an alkyl group or hydroxyl; Z is a C.sub.1-10 saturated or unsaturated hydrocarbon forming a straight-chain, a branched-chain or a ring, which is unsubstituted or substituted by halogen, an alkyl group, an alkoxy group, hydroxyl, a phenyl group or a phenoxy group; or the physiologically acceptable salts and carboxylic acid esters of the compounds of formula (I) said ester being a straight or branched-chain alkyl containing up to one unsaturated bond, cycloalkyl, benzyl, phenyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl or tetrahydropyranyl ester, of a compound of Formula (I); and a pharmaceutically acceptable carrier.

2. A method for treating ocular hypertension in a human patient needing such treating which comprises administering to said patient an amount of a 13,14-dihydro-15-keto-prostaglandin of the formula (I) effective to treat ocular hypertension ##STR18## wherein A is ##STR19## wherein R is hydroxy, hydroxy C.sub.1-3 alkyl or C.sub.1-2 alkyl; Y is a saturated or unsaturated C.sub.2-6 hydrocarbon chain which is unsubstituted or substituted by oxo, halogen, an alkyl group or hydroxyl; Z is a C.sub.1-10 saturated or unsaturated hydrocarbon forming a straight-chain, a branched-chain or a ring, which is unsubstituted or substituted by halogen, an alkyl group, an alkoxy group, hydroxyl, a phenyl group or a phenoxy group; or the physiologically acceptable salts and carboxylic acid esters of the compounds of formula (I) said ester being a straight or branched-chain alkyl containing up to one unsaturated bond, cycloalkyl, benzyl, phenyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl or tetrahydropyranyl ester, of a compound of Formula (I).

3. A method for treating glaucoma in a human patient needing such treatment which comprises administering to said patient an amount of a 13,14-dihydro-15-keto-prostaglandin of the following formula (I) effective to treat glaucoma ##STR20## wherein A is ##STR21## wherein R is hydroxy, hydroxy C.sub.1-3 alkyl of C.sub.1-2 alkyl; Y is a saturated or unsaturated C.sub.2-6 hydrocarbon chain which is unsubstituted or substituted by oxo, halogen, an alkyl group or hydroxyl; Z is a C.sub.1-10 saturated or unsaturated hydrocarbon forming a straight-chain, a branched-chain or a ring, which is unsubstituted or substituted by halogen, an alkyl group, an alkoxy group, hydroxyl, a phenyl group or a phenoxy group; or the physiologically acceptable salts and carboxylic acid esters of the compounds of formula (I) said ester being a straight or branched-chain alkyl containing up to one unsaturated bond, cycloalkyl, benzyl, phenyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl or tetrahydropyranyl ester, a the compound of Formula (I).

4. The method of claim 2, wherein the carboxyl group at the end of the .alpha.-chain in the 13,14-dihydro-15-keto-prostaglandin is in the form of an alkyl ester.

5. The method of claim 2, wherein the 13,14-dihydro-15-keto-prostaglandin is in the form of a 20-alkyl having an alkyl group at the C-20 position.

6. The method of claim 2, wherein the 13,14-dihydro-15-keto-prostaglandin is a prostaglandin of the A series.

7. The method of claim 2, wherein the 13,14-dihydro-15-keto-prostaglandin is a prostaglandin of the B series.

8. The method of claim 2, wherein the 13,14-dihydro-15-keto-prostaglandin is a prostaglandin of the C series.

9. The method of claim 2, wherein the 13,14-dihydro-15-keto-prostaglandin is a prostaglandin of the D series.

10. The method of claim 2, wherein the 13,14-dihydro-15-keto-prostaglandin is a prostaglandin of the J series.

11. The method of any of claims 2 or 4-10, wherein said administration s topically to the eye.

12. The method of claim 3, wherein the carboxyl group at the end of the .alpha.-chain in the 13,14-dihydro-15-keto-prostaglandin is in the form of an alkyl ester.

13. The method of claim 3, wherein the 13,14-dihydro-15-keto-prostaglandin is in the form of a 20-alkyl having an alkyl group at the C-20 position.

14. The method of claim 3, wherein the 13,14-dihydro-15-keto-prostaglandin is a prostaglandin of the A series.

15. The method of claim 3, wherein the 13,14-dihydro-15-keto-prostaglandin is a prostaglandin of the B series.

16. The method of claim 3, wherein the 13,14-dihydro-15-keto-prostaglandin is a prostaglandin of the C series.

17. The method of claim 3, wherein the 13,14-dihydro-15-keto-prostaglandin is a prostaglandin of the D series.

18. The method of claim 3, wherein the 13,14-dihydro-15-keto-prostaglandin is a prostaglandin of the J series.

19. The method of any of claims 4 or 12-19, wherein said administration is topically to the eye.

20. The ocular hypotensive composition according to claim 1, wherein the carboxyl group at the end of the .alpha.-chain in the 13,14-dihydro-15-keto-prostaglandin is in the form of an alkyl ester.

21. The ocular hypotensive compositions according to claim 1, wherein the 13,14-dihydro-15-keto-prostaglandin is in the form of 20-alkyl having an alkyl group at the C-20 position.

22. The ocular hypotensive compositions according to claim 1, wherein the 13,14-dihydro-15-keto-prostaglandin is a prostaglandin of the A series.

23. The ocular hypotensive compositions according to claim 1, wherein the 13,14-dihydro-15-keto-prostaglandin is a prostaglandin of the B series.

24. The ocular hypotensive compositions according to claim 1, wherein the 13,14-dihydro-15-keto-prostaglandin is a prostaglandin of the C series.

25. The ocular hypotensive compositions according to claim 1, wherein the 13,14-dihydro-15-keto-prostaglandin is a prostaglandin of the D series.

26. The ocular hypotensive compositions according to claim 1, wherein the 13,14-dihydro-15-keto-prostaglandin is a prostaglandin of the J series.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc